semaglutide and chronic kidney disease Long-term outcomes of in obesity cardiovascular in the SELECT trial Presented at #ERA24: FLOW trial:

[5] [6] The medication is a synthetic analog of human GLP-1, modified with an albumin side chain that extends its half-life to approximately one week, allowing for once-weekly subcutaneous administration or daily oral dosing

But even 11.3% is higher than semaglutide's 6.9%

Resources like Ozempic alternatives help you navigate this transition with confidence

Animal studies provide valuable information, but this often means more research is required before it applies to humans

In head-to-head weight-loss trials, tirzepatide produces slightly greater weight loss than semaglutide on average

Despite their differences, both drugs work by augmenting a hormone that controls blood sugar and appetite